Epigenetic down-regulation of SOX2 is an independent poor prognostic factor for hypopharyngeal cancers

2018 ◽  
Vol 72 (5) ◽  
pp. 826-837 ◽  
Author(s):  
Mehmet Ozgur Avincsal ◽  
Naoe Jimbo ◽  
Kohei Fujikura ◽  
Hirotaka Shinomiya ◽  
Naoki Otsuki ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Down Regulation ◽  
Poor Prognostic Factor ◽  
Independent Poor Prognostic Factor

NDRG2 Is Involved in the Oncogenic Properties of Renal Cell Carcinoma and Its Loss Is a Novel Independent Poor Prognostic Factor After Nephrectomy

2012 ◽  
Vol 19 (8) ◽  
pp. 2763-2772 ◽  
Author(s):  
Zhe Long Liang ◽  
Kyeongah Kang ◽  
Sukjoon Yoon ◽  
Song Mei Huang ◽  
Jae Sung Lim ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Poor Prognostic Factor ◽  
Independent Poor Prognostic Factor

Wilms’ Tumor 1 Gene Mutations in Childhood Acute Myeloid Leukemia: A New Prognostic factor with Implications for MRD Detection

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 144-144 ◽  
Author(s):  
Iris H.I.M. Hollink ◽  
Marry M. van den Heuvel-Eibrink ◽  
Martin Zimmermann ◽  
Brian V. Balgobind ◽  
Susan T.C.J.M. Arentsen-Peters ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Gene Mutations ◽  
Wt1 Gene ◽  
Wild Type ◽  
Poor Prognostic Factor ◽  
Free Survival ◽  
Independent Poor Prognostic Factor ◽  
Mutational Hotspots ◽  
Childhood Aml ◽  
Wt1 Mutation

Abstract In an array-CGH screening study of cytogenetically normal AML (CN-AML), we detected a cryptic 11p13-deletion including the WT1 gene in one childhood AML sample. The remaining WT1 allele in this sample carried a nonsense mutation. WT1 gene mutations have recently been identified in approximately 10% of adult CN-AML. Of interest, WT1 mutations were found to be a new independent poor prognostic factor in adult CN-AML (Virappane et al. JCO2008, Paschka et al. JCO2008). WT1 mutations have also been reported in childhood AML; however, their clinical relevance in childhood AML is not known. In this study, we investigated the frequency, clinical characteristics and prognostic value of WT1 mutations (exons 7–10) in a large, well-characterized cohort of childhood AML samples (n=298). Additionally, a subset of these samples was screened for mutations in exons 1–6 (n=68), and for micro-deletions in the WT1 gene (n=24). Survival analysis was restricted to the subset of patients with de novo AML who were treated using uniform DCOG and BFM treatment protocols (n=232). Fifty-three pathogenic WT1 mutations were detected in 35/298 (12%) samples taken at diagnosis. Mutations were mainly located in exon 7 (n=43), but also in exons 1 (n=2), 2 (n=1), 3 (n=2), 8 (n=1) and 9 (n=4). Predominantly frame-shift mutations were found (n=41), next to nonsense mutations (n=6) and missense mutations (n=6); the former two resulting in a truncated WT1 protein. In 19/35 (54%) of the WT1-mutated samples, we detected more than one WT1 aberration. This included either a different WT1 mutation (n=15), a homozygous WT1 mutation (n=2), or a deletion of the other WT1 allele (n=2). WT1 mutations clustered significantly in the CN-AML subgroup (21/94=22%; p<0.001). NPM1 and WT1 mutations were mutually exclusive, but WT1-mutated samples were more likely to carry FLT3/ITD (43% vs. 17%; p<0.001) and CEBPα mutations (26% vs. 9%; p=0.007). Mutations in patients below the age of 3 years were only found sporadically (1/60=2%). The highest frequency was found in the age category 3–10 years (17/76=18%), and decreased above the age of 10 years (17/128=12%; p=0.008). WT1-mutated AML was correlated with a higher white blood cell count at diagnosis (WBC) (57.2×109/l vs. 34.1×109/l; p=0.007); no correlation was found with sex or FAB-classification. WT1-mutated AML patients had a significantly worse outcome when compared with patients with WT1 wild-type AML (5-year overall survival (pOS) 35% vs. 66%; p=0.002; 5-year event-free survival (pEFS) 22% vs. 46%; p<0.001; and 5-year cumulative incidence of relapses (CIR) 70% vs. 44%, respectively; pGray<0.001). Moreover, using multivariate analysis including age, WBC, cytogenetics, FLT3/ITD and stem cell transplantation, WT1 mutations were identified as an independent poor prognostic factor for pOS (HR1.79; p=0.04), pEFS (HR2.05; p=0.005) and relapse-free survival (pRFS) (HR2.44; p=0.001). We identified patients carrying both a WT1 mutation as well as a FLT3/ITD as a very poor prognostic subgroup (5-year pOS 21%). The mutational hotspots in the WT1 gene were located within areas of primer-probe combinations used for WT1-based minimal residual disease (MRD) detection. Furthermore, in 4/28 (14%) wild-type diagnostic-relapse pairs a mutation was gained at relapse, which may also effect MRD detection. In conclusion, WT1 mutations are present in 12% of childhood AML at diagnosis and in 22% of patients with CN-AML, and are a novel independent poor prognostic marker in childhood AML. Furthermore, their presence may have implications for current WT1-based MRD detection.

Dual Translocation Is An Independent Poor Prognostic Factor in Diffuse Large B-Cell Lymphoma,

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3683-3683
Author(s):  
Kevin Tay ◽  
Gillianne Lai ◽  
Elaine J Chua ◽  
Whee Sze Ong ◽  
Tiffany Tang ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Prognostic Factor ◽  
Cell Lymphoma ◽  
Bone Marrow Involvement ◽  
B Cell Lymphoma ◽  
Survival Outcomes ◽  
Poor Prognostic Factor ◽  
Large B Cell Lymphoma ◽  
Independent Poor Prognostic Factor ◽  
Large B Cell

Abstract Abstract 3683 Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogenous group of diseases, that are associated with variable survival outcomes depending on the presence of certain genetic and molecular features. Of particular interest is a subset known as the “double-hit” (DH) lymphoma. DH lymphoma (dual translocation) is defined by the presence of a chromosomal breakpoint affecting the MYC/8q24 locus with a second oncogene translocation, most commonly a BCL2 rearrangement, and less commonly involving BCL6 or CCND1 rearrangements. However, the incidence of DH lymphoma remains to be determined. These patients typically have poor prognostic factors, with a dismal outcome when treated with rituximab-CHOP (RCHOP) chemotherapy. The aim of this study was to identify any clinical defining characteristics in patients with DH lymphoma, and to compare their outcomes with that of DLBCL patients without dual translocation. Methods: 202 newly diagnosed DLBCL patients, of whom 90% received rituximab based chemotherapy, were investigated using immunohistochemistry and fluorescence in situ hybridization (FISH), using breakapart FISH probes targeting BCL2, BCL6, MYC, CCND1 and IgH genes. The clinical characteristics and survival outcomes of patients who were identified with DH lymphoma were compared to those without the dual translocation. Results: Out of the 202 patients with DLBCL, we identified 10 cases (5%) with two or more concurrent translocations involving MYC and BCL2, or MYC and BCL6. Among the 10 patients with DH lymphoma, there were 6 patients with concurrent BCL2 and MYC translocations, 1 patient with BCL6 and MYC translocations and 3 patients with all 3 abnormalities. 7 of the 10 patients were male, with a median age of 68 years (42 – 84). Patients with DH lymphoma also presented with a significantly higher incidence of high-risk clinical features, including advanced stage disease, bulky disease, extranodal disease, bone marrow involvement and a high IPI score. Interestingly, the majority of patients with DH lymphoma expressed a germinal center (GC) phenotype (8 out of 9 patients) based on the Han's criteria. These patients also demonstrated a significantly poorer overall survival (OS) when compared to patients without dual translocation (2 yr OS 33% vs 84%, p = < 0.001). On multivariate analysis, the presence of a dual translocation was found to be an independent poor prognostic factor for OS (hazard ratio 8.84, 95% CI 3.54 to 22.08). Other factors predictive of an inferior OS included age, stage, bone marrow involvement and patients treated without rituximab. Conclusions: Our findings showed that the presence of dual translocation is an independent poor prognostic factor in DLBCL. It was present in 5% of our cohort and was associated with more advanced disease. Patients with dual translocation also had a significantly poorer survival following treatment with standard chemotherapy such as RCHOP, even though most patients exhibited the GC phenotype. Therefore, the use of novel agents in combination with chemotherapy is an area that deserves further exploration in this type of lymphoma. Disclosures: No relevant conflicts of interest to declare.

Monosomal karyotype of chromosome 5/7 was an independent poor prognostic factor for Chinese myelodysplastic syndrome patients

2016 ◽  
Vol 209 (9) ◽  
pp. 423-429 ◽  
Author(s):  
Tongtong Zhang ◽  
Yang Xu ◽  
Jinlan Pan ◽  
Huiying Qiu ◽  
Depei Wu ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Myelodysplastic Syndrome ◽  
Chromosome 5 ◽  
Poor Prognostic Factor ◽  
Independent Poor Prognostic Factor ◽  
Monosomal Karyotype

scholarly journals CDKN2B methylation is an independent poor prognostic factor in newly diagnosed acute promyelocytic leukemia

Leukemia ◽  
2005 ◽  
Vol 20 (1) ◽  
pp. 149-151 ◽  
Author(s):  
C-S Chim ◽  
J S Lau ◽  
K-F Wong ◽  
Y-L Kwong
Keyword(s):  
Prognostic Factor ◽  
Acute Promyelocytic Leukemia ◽  
Promyelocytic Leukemia ◽  
Newly Diagnosed ◽  
Poor Prognostic Factor ◽  
Independent Poor Prognostic Factor

6512 POSTER Stromal Cell-derived Factor-1 Alpha is a Novel Independent Poor Prognostic Factor in Gallbladder Carcinoma

2011 ◽  
Vol 47 ◽  
pp. S445-S446
Author(s):  
H.J. Lee ◽  
Y.S. Oh ◽  
Z.L. Liang ◽  
H.Y. Kim ◽  
H.J. Yun ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Gallbladder Carcinoma ◽  
Stromal Cell ◽  
Poor Prognostic Factor ◽  
Independent Poor Prognostic Factor ◽  
Stromal Cell Derived Factor

Loss of PTEN Expression is an Independent Poor Prognostic Factor in Non-small Cell Lung Cancer

2011 ◽  
Vol 45 (4) ◽  
pp. 329 ◽  
Author(s):  
Seol Bong Yoo ◽  
Xianhua Xu ◽  
Hyun Ju Lee ◽  
Sanghoon Jheon ◽  
Choon-Taek Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Pten Expression ◽  
Small Cell Lung ◽  
Poor Prognostic Factor ◽  
Independent Poor Prognostic Factor

L1 cell adhesion molecule as a novel independent poor prognostic factor in gallbladder carcinoma

2011 ◽  
Vol 42 (10) ◽  
pp. 1476-1483 ◽  
Author(s):  
Song-Yi Choi ◽  
Young Suk Jo ◽  
Song-Mei Huang ◽  
Zhe Long Liang ◽  
Jeong-Ki Min ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
Prognostic Factor ◽  
Adhesion Molecule ◽  
Gallbladder Carcinoma ◽  
Cell Adhesion Molecule ◽  
Poor Prognostic Factor ◽  
Independent Poor Prognostic Factor ◽  
L1 Cell Adhesion Molecule
Sign in / Sign up

Export Citation Format

Share Document